Abstract
It has been shown that prolactin (PRL) induces glucose intolerance, hyperinsulinemia and insulin resistance in several animal species. In women with microprolactinomas, the sensitivity to insulin is lower in hyperprolactinemia than in normoprolactinemia. Thirty non-obese women with hyperprolactinemia and 30 healthy non-obese women were included into the study. Age, body weight (bw), height, body mass index (BMI), waist circumference, hip circumference and waist to hip ratio of both patients with hyperprolactinemia and control sub-jects were not different. Mean serum prolactin level was higher in hyperprolactinemic patients than in control group (84.5±51.1 ng/ml and 13.8±5.3 ng/ml respectively, p<0.002). Mean HOMA-(%B) index of hyperprolactinemic patients was higher than in control subjects (121±49 and 84±38, respectively, p<0.02). Mean HOMA-(%S) index was lower in hyper-prolactinemic patients (56±39 and 105±55, respectively, p<0.006). Serum total testosterone, free testosterone, androstenedione, estradiol, cortisol, sex hormone binding globulin and DHEA-S levels in both hyperprolactinemic women and healthy subjects, statistically did not show any difference between the two groups. The present data indicate that hyperpro-lactinemia is associated with an insulin-resistant state. This resistant state may not be a result of obesity, androgenic hormones, and SHBG or pregnancy. It may be the result of serum free fatty acids (FFA) levels, decrement in the number of insulin receptors (by a down-regulation of insulin receptors) or post-binding defect in insulin action or more.
Similar content being viewed by others
References
Pijl H., Ohashi S., Matsuda M., et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000, 23: 1154–1161.
Reis F.M., Reis A.M., Coimbra C.C. Effects of hyperpro-lactinemia on glucose tolerance and insulin release in male and female rats. J. Endocrinol. 1997, 153: 423–428.
Matsuda M., Mori T. Effect of estrogen on hyperpro-lactinemia- induced glucose intolerance in SHN mice. Proc. Soc. Exp. Biol. Med. 1996, 212: 243–247.
Serri O., Beauregard H., Rasio E., Hardy J. Decreased sensitivity to insulin in women with microprolactinomas. Fertil. Steril. 1986, 45: 572–574.
Gustafson A.B., Banasiak M.F., Kalkhoff R.K., Hagen T.C., Kim H.J. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J. Clin. Endocrinol. Metab. 1980, 51: 242–246.
Johnston D.G., Alberti K.G., Nattrass M., Burrin J.M., Blesa-Malpica G., Hall K., Hall R. Hyperinsulinaemia in hy-perprolactinaemic women. Clin. Endocrinol. (Oxf.) 1980 13: 361–368.
Seki K., Nagata I. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma. Gynecol. Obstet. Invest. 1991, 31: 222–225.
Schernthaner G., Prager R., Punzengruber C., Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985, 28: 138–142.
Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment:insulin resitance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412–419.
Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 2002, 32: 14–23.
Beck-Nielsen H. Insulin resistance: Organ manifestations and cellular mechanisms. Ugeskr. Laeger. 2002, 164: 2130–2135.
Hartman H.B., Hu X., Tyler K.X., Dalal C.K., Lazar M.A. Mechanisms regulating adipocyte expression of resistin. J. Biol. Chem. 2002, 277: 19754–19761.
Foss M.C., Paula F.J., Paccola G.M., Piccinato C.E. Peripheral glucose metabolism in human hyperprolactinemia. Clin. Endocrinol. (Oxf.) 1995, 43: 721–726.
Puavilai G., Drobny E.C., Domont L.A., Baumann G. Insulin receptors and insulin resistance in human pregnancy: evidence for a postreceptor defect in insulin action. J. Clin. Endocrinol. Metab. 1982, 54: 247–253.
Aron D.C., Findling J.W., Tyrrell J.B. Hypothalamus and Pituitary. In: Greenspan F.S., Strewler G.J. (Eds.), Basic and clinical Endocrinology, ed. 5. Appleton and Lange, Connecticut, 1997, P. 109.
Ryan E.A., Enns L. Role of gestational hormones in the induction of insulin resistance. J. Clin. Endocrinol. Metab, 1988, 67: 341–347.
Kim S.Y., Sung Y.A., Ko K.S., et al. Direct relationship between elevated free testosterone and insulin resistance in hyperprolactinemic women. Korean J. Intern. Med. 1993, 8: 8–14.
Falcone T., Meltzer S., Morris D. Effect of hyperpro-lactinemia on the androgen response to an oral glucose load. Fertil. Steril. 1992, 58: 1119–1122.
Cincotta A.H., Meier A.H., Cincotta Jr. M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert. Opin. Investig. Drugs. 1999, 8: 1683–1707.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tuzcu, A., Bahceci, M., Dursun, M. et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26, 341–346 (2003). https://doi.org/10.1007/BF03345182
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345182